News | September 02, 2025
Zydus launches VaxiFlu vaccine for flu protection
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
mRNA-1010 demonstrated superior relative vaccine efficacy
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Subscribe To Our Newsletter & Stay Updated
